Latest News
News Functions
Additional Functions
13 September 2024
CureVac
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
12 September 2024
CureVac
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
9 September 2024
CureVac
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
15 August 2024
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
CureVac
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
CureVac
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
11 July 2024
CureVac
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
3 July 2024
CureVac
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
CureVac
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
24 June 2024
CureVac
CureVac Announces Voting Results of General Meeting
28 May 2024
CureVac
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
23 May 2024
CureVac
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
24 April 2024
CureVac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
CureVac
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
CureVac
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
18 April 2024
CureVac
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
16 April 2024
CureVac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4 April 2024
CureVac
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
5 January 2024
CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
19 December 2023
CureVac
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
14 November 2023
CureVac
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
1 November 2023
CureVac
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
28 September 2023
CureVac
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
12 September 2023
CureVac
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
17 August 2023
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
1 August 2023
CureVac
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
14 July 2023
CureVac
CureVac Announces Update to the Management Team
13 July 2023
CureVac
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
20 June 2023
CureVac
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
CureVac
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board